Abstract
BackgroundDespite significant cost differences, the comparative effect of combination treatments of disease modifying anti-rheumatic drugs (DMARDs) with and without biologic agents has rarely been examined. Thus we performed a network meta-analysis on the effect of combination therapies on progression of radiographic joint erosions in patients with rheumatoid arthritis (RA).Methods and FindingsThe following combination drug therapies compared versus single DMARD were investigated: Double DMARD: 2 DMARDs (methotrexate, sulfasalazine, leflunomide, injectable gold, cyclosporine, chloroquine, azathioprin, penicillamin) or 1 DMARD plus low dose glucocorticoid (LDGC); triple DMARD: 3 DMARDs or 2 DMARDs plus LDGC; biologic combination: 1 DMARD plus biologic agent (tumor necrosis factor α inhibitor (TNFi) or abatacept or tocilizumab or CD20 inhibitor (CD20i)). Randomized controlled trials were identified in a search of electronic archives of biomedical literature and included in a star-shaped network meta-analysis and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement protocol. Effects are reported as standardized mean differences (SMD). The effects of data from 39 trials published in the period 1989–2012 were as follows: Double DMARD: −0.32 SMD (CI: −0.42, −0.22); triple DMARD: −0.46 SMD (CI: −0.60, −0.31); 1 DMARD plus TNFi: −0.30 SMD (CI: −0.36, −0.25); 1 DMARD plus abatacept: −0.20 SMD (CI: −0.33, −0.07); 1 DMARD plus tocilizumab: −0.34 SMD (CI: −0.48, −0.20); 1 DMARD plus CD20i: −0.32 SMD (CI: −0.40, −0.24). The indirect comparisons showed similar effects between combination treatments apart from triple DMARD being significantly better than abatacept plus methotrexate (−0.26 SMD (CI: −0.45, −0.07)) and TNFi plus methotrexate (−0.16 SMD (CI: −0.31, −0.01)).ConclusionCombination treatment of a biologic agent with 1 DMARD is not superior to 2–3 DMARDs including or excluding LDGC in preventing structural joint damage. Future randomized studies of biologic agents should be compared versus a combination of DMARDs.
Highlights
Future randomized studies of biologic agents should be compared versus a combination of disease modifying anti-rheumatic drugs (DMARDs)
In a meta-analysis of 70 randomized controlled trials (RCTs) of rheumatoid arthritis (RA) patients investigating the effect of drug treatment on radiographic joint destruction, disease modifying anti rheumatic drugs (DMARDs), low-dose glucocorticoids (LDGC), biologic agents, and combinations of these significantly reduced radiographic progression with a relative effect of 48–84% compared with placebo treatment [1]
As our previous study [1] indicated that combination drug treatment was effective irrespective of the drugs involved in the combination, we intended to test the hypothesis that in patients with RA combination treatments of at least two DMARDs, or at least one DMARD plus LDGC or one DMARD plus a biologic agent do not differ significantly in their ability to reduce radiographic joint destruction when compared with a single DMARD
Summary
In a meta-analysis of 70 randomized controlled trials (RCTs) of rheumatoid arthritis (RA) patients investigating the effect of drug treatment on radiographic joint destruction (erosions), disease modifying anti rheumatic drugs (DMARDs), low-dose glucocorticoids (LDGC), biologic agents, and combinations of these significantly reduced radiographic progression with a relative effect of 48–84% compared with placebo treatment [1]. As our previous study [1] indicated that combination drug treatment was effective irrespective of the drugs involved in the combination, we intended to test the hypothesis that in patients with RA combination treatments of at least two DMARDs, or at least one DMARD plus LDGC or one DMARD plus a biologic agent do not differ significantly in their ability to reduce radiographic joint destruction (erosions) when compared with a single DMARD. We performed a network meta-analysis on the effect of combination therapies on progression of radiographic joint erosions in patients with rheumatoid arthritis (RA)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
